Fragment-Based Drug Discovery icon  

Twelfth Annual

Fragment-Based Drug Discovery

From Hits to Leads and Lessons Learned

April 25-26, 2017

Fragment-based drug discovery (FBDD) approaches are now common in lead generation. Two compounds originating from fragment-based campaigns have made it all the way to market and at least thirty fragment-derived drug candidates are in clinical trials. The oldest fragment-focused annual conference in the field, this meeting will continue to enable FBDD practitioners to share best practices and learn from one another. Evolving thoughts on qualities of a good library, advances in screening techniques, and the challenges of transforming fragments to leads will all be part of the agenda.

Topics will include, but are not limited to:

  • Fragment library screening methods: X-ray crystallography advances, SPR screening, NMR challenges, cryoEM – Possibilities for automation and screening?
  • Case studies on growing fragment hits to leads and integrating leads from HTS screens
  • Updates on new FBDD-derived compounds entering the clinic
  • Medicinal chemists’ retrospective tracing of their FBDD-originated compounds now on the market or in late stage clinical development
  • Perspectives on features of a good fragment library
  • FBDD approaches for epigenetic targets
  • FBDD approaches for allosteric modulators of PPIs

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is October 7, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

We hope you can join us for this day-and-a-half conference (one of four parallel tracks) that is in the second half of our larger Drug Discovery Chemistry event. Attending this meeting enables you to also hop to concurrent meeting tracks to hear other presentations of interest.

For more details on the conference, please contact:
Anjani Shah, Ph.D.
Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-247-6252

For partnering and sponsorship information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412